Machina Capital S.A.S. Has $787,000 Holdings in Incyte Corporation $INCY

Machina Capital S.A.S. boosted its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 44.6% in the second quarter, HoldingsChannel reports. The firm owned 11,557 shares of the biopharmaceutical company’s stock after acquiring an additional 3,563 shares during the period. Machina Capital S.A.S.’s holdings in Incyte were worth $787,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Amalgamated Bank increased its stake in shares of Incyte by 1.9% in the first quarter. Amalgamated Bank now owns 31,551 shares of the biopharmaceutical company’s stock valued at $1,910,000 after buying an additional 591 shares in the last quarter. Principal Financial Group Inc. lifted its position in Incyte by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 213,947 shares of the biopharmaceutical company’s stock worth $12,954,000 after buying an additional 1,419 shares in the last quarter. IFM Investors Pty Ltd grew its holdings in Incyte by 15.4% during the 1st quarter. IFM Investors Pty Ltd now owns 36,744 shares of the biopharmaceutical company’s stock worth $2,429,000 after acquiring an additional 4,907 shares during the last quarter. Bank of New York Mellon Corp increased its position in Incyte by 8.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,223,136 shares of the biopharmaceutical company’s stock valued at $74,061,000 after acquiring an additional 95,621 shares in the last quarter. Finally, Blackhawk Capital Partners LLC. raised its stake in shares of Incyte by 4.4% in the first quarter. Blackhawk Capital Partners LLC. now owns 4,135 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 175 shares during the last quarter. Institutional investors own 96.97% of the company’s stock.

Incyte Stock Performance

INCY stock opened at $101.57 on Tuesday. Incyte Corporation has a twelve month low of $53.56 and a twelve month high of $101.79. The company has a quick ratio of 2.78, a current ratio of 3.20 and a debt-to-equity ratio of 0.01. The company has a market cap of $19.94 billion, a P/E ratio of 17.01, a price-to-earnings-growth ratio of 0.70 and a beta of 0.73. The business’s fifty day moving average is $86.64 and its 200-day moving average is $75.28.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price target on shares of Incyte from $73.00 to $89.00 and gave the company a “neutral” rating in a research note on Thursday, October 9th. Citigroup upped their price objective on Incyte from $88.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, July 30th. Guggenheim upgraded Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price objective on the stock in a research report on Monday. UBS Group restated a “neutral” rating and set a $68.00 target price (up previously from $62.00) on shares of Incyte in a research report on Wednesday, July 30th. Finally, BMO Capital Markets reiterated an “underperform” rating and issued a $60.00 price target (up previously from $52.00) on shares of Incyte in a report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $92.00.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.